What Is Metformin?
Metformin is a biguanide oral antihyperglycemic agent and the first-line pharmacotherapy for type 2 diabetes mellitus worldwide. Developed from the French lilac (Galega officinalis), metformin has been in clinical use for over 60 years and is one of the most prescribed medications globally. It is valued for its efficacy in lowering blood glucose, favorable safety profile, low risk of hypoglycemia when used as monotherapy, and additional benefits including modest weight reduction and improved cardiovascular outcomes. Metformin is included on the World Health Organization Model List of Essential Medicines.
Mechanism of Action
Metformin primarily acts by suppressing hepatic gluconeogenesis (glucose production by the liver) and reducing intestinal glucose absorption. It enhances peripheral insulin sensitivity by increasing glucose uptake and utilization in muscle and adipose tissue. At the molecular level, metformin activates AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis. AMPK activation leads to inhibition of gluconeogenic enzymes and increased fatty acid oxidation. Unlike sulfonylureas, metformin does not stimulate insulin secretion, which explains its low hypoglycemia risk. It also improves lipid profiles by reducing LDL cholesterol and triglycerides while mildly increasing HDL cholesterol.
Approved Uses
- Type 2 Diabetes: First-line pharmacotherapy for glycemic control, used in conjunction with lifestyle modifications (diet and exercise).
- Prediabetes: May delay or prevent progression to type 2 diabetes in high-risk individuals with impaired glucose tolerance.
- Gestational Diabetes: Used as an alternative to insulin in some cases of gestational diabetes (off-label in some regions).
- Polycystic Ovary Syndrome (PCOS): Frequently used off-label to improve insulin resistance and restore ovulatory function.
Dosage Forms and Strengths
| Form | Strength | Starting Dose | Maximum Daily Dose |
|---|---|---|---|
| Immediate-release tablet | 500 mg | 500 mg once or twice daily | 2000–2550 mg |
| Immediate-release tablet | 850 mg | 500 mg once or twice daily | 2000–2550 mg |
| Extended-release tablet | 500 mg | 500 mg once daily (with evening meal) | 2000 mg |
| Extended-release tablet | 750 mg | 500 mg once daily (with evening meal) | 2000 mg |
Metformin should be taken with meals to minimize gastrointestinal side effects. Extended-release formulations are preferred for patients who experience significant GI intolerance with immediate-release formulations.
Side Effects and Safety Profile
Gastrointestinal side effects are the most common, including diarrhea, nausea, vomiting, bloating, and abdominal discomfort. These are typically dose-related and often improve over time with gradual dose titration. The most serious (though rare) adverse effect is lactic acidosis, which occurs primarily in patients with contraindicated conditions such as severe renal impairment (eGFR <30 mL/min/1.73 m²), acute congestive heart failure, or severe hepatic disease. Long-term metformin use may lead to vitamin B12 deficiency, and periodic screening is recommended. Metformin does not cause hypoglycemia when used as monotherapy but may potentiate the hypoglycemic effects of sulfonylureas or insulin.
Comparison: Metformin vs Other Diabetes Medications
| Drug Class | Example | Mechanism | Hypoglycemia Risk | Weight Effect |
|---|---|---|---|---|
| Biguanide | Metformin | Reduces hepatic glucose output | Low | Neutral/slight loss |
| Sulfonylurea | Glimepiride | Stimulates insulin secretion | Moderate | Weight gain |
| SGLT2 Inhibitor | Dapagliflozin | Blocks renal glucose reabsorption | Low | Weight loss |
| DPP-4 Inhibitor | Sitagliptin | Increases incretin levels | Low | Neutral |
| GLP-1 Agonist | Liraglutide | Increases insulin, slows gastric emptying | Low | Weight loss |
Clinical Efficacy and Key Studies
The landmark UK Prospective Diabetes Study (UKPDS), published in The Lancet in 1998, demonstrated that intensive glucose control with metformin in overweight patients with newly diagnosed type 2 diabetes reduced diabetes-related endpoints by 32%, diabetes-related deaths by 42%, and all-cause mortality by 36% compared to conventional diet-based management. Notably, metformin outperformed sulfonylureas and insulin in reducing cardiovascular risk, establishing its position as first-line therapy. Long-term follow-up of UKPDS patients revealed durable glycemic benefits and sustained cardiovascular risk reduction even after the trial period, a phenomenon termed the “legacy effect.” The Diabetes Prevention Program (DPP) further demonstrated that metformin reduced the incidence of type 2 diabetes by 31% compared with placebo in high-risk individuals with prediabetes, supporting its use in diabetes prevention strategies.
Drug Interactions
Metformin has a relatively favorable drug interaction profile, but several clinically important interactions warrant attention. Cationic drugs that are eliminated by renal tubular secretion, such as cimetidine, ranolazine, dolutegravir, and certain antiarrhythmics, can compete with metformin for organic cation transporter (OCT) pathways, potentially increasing metformin exposure. Concomitant use of carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide) may increase the risk of lactic acidosis. Corticosteroids, thiazide diuretics, beta-agonists, and thyroid products may cause hyperglycemia and reduce metformin efficacy. Alcohol consumption potentiates metformin’s effect on lactate metabolism and should be limited or avoided, particularly in patients with hepatic impairment or a history of binge drinking. Iodinated contrast agents require temporary metformin discontinuation (typically 48 hours before and after procedure) due to the risk of acute renal impairment and consequent lactic acidosis.
Clinical Pharmacology and Pharmacokinetics
Metformin is a hydrophilic base that exists as a cationic species at physiological pH. Following oral administration, it is absorbed primarily from the small intestine with an absolute bioavailability of 50–60%. Absorption is saturable and dose-dependent. The drug is rapidly distributed into peripheral tissues, with negligible plasma protein binding. Metformin is not metabolized by hepatic cytochrome P450 enzymes and is excreted unchanged in the urine via active tubular secretion mediated by organic cation transporters (OCT1, OCT2, and MATE1/2). The plasma elimination half-life is approximately 6.2 hours. Renal clearance is approximately 500 mL/min, significantly exceeding glomerular filtration rate, confirming active tubular secretion. Impaired renal function substantially prolongs metformin half-life and increases plasma concentrations, necessitating dose adjustment and eGFR-based monitoring.
Special Population Considerations
Pediatric patients: Metformin is approved for use in children aged 10 years and older with type 2 diabetes, starting at 500 mg once daily, titrated slowly to a maximum of 2000 mg daily. Geriatric patients: Elderly patients are at increased risk of metformin accumulation due to age-related decline in renal function. More frequent renal monitoring (every 3–6 months) and conservative dosing are recommended. Hepatic impairment: Metformin is contraindicated in patients with severe hepatic impairment due to increased lactic acidosis risk. Renal impairment: Current FDA guidance permits metformin use with dose reduction at eGFR 30–45 mL/min/1.73 m² and contraindicates it at eGFR below 30. In patients with eGFR 30–45, metformin dose should not exceed 1000 mg daily, and eGFR should be monitored at least every 6 months.
Patient Counseling Information
Patients should be advised to take metformin with meals to minimize gastrointestinal side effects. Extended-release formulations should be taken once daily with the evening meal, and tablets should not be crushed, chewed, or split. Gradual dose titration over 2–4 weeks significantly improves gastrointestinal tolerability. Patients should be counseled about the symptoms of lactic acidosis (unexplained hyperventilation, myalgia, abdominal pain, lethargy, hypothermia) and advised to seek immediate medical attention if these develop. Metformin should be temporarily discontinued before any surgical procedure involving restricted food and fluid intake, before iodinated contrast imaging studies, and during acute illness with dehydration. Patients should also be educated that metformin does not cause hypoglycemia as monotherapy but can augment the blood glucose-lowering effects of insulin and sulfonylureas, requiring appropriate dose adjustments.
Available Brands and Manufacturers
Generic metformin is manufactured by dozens of companies globally. In India, leading producers include USV Private Limited (Glycomet), Cipla, Sun Pharma, Dr. Reddy’s Laboratories, Aurobindo Pharma, Torrent Pharmaceuticals, and Ipca Laboratories. The Indian pharmaceutical industry supplies a significant proportion of the world’s generic metformin, with WHO-GMP certified manufacturing facilities ensuring quality. Extended-release formulations are also widely available under various brand names and are often preferred for their once-daily dosing convenience and improved gastrointestinal tolerability compared to immediate-release metformin.
Metformin and Cancer Risk
Observational studies and meta-analyses have suggested an association between metformin use and reduced cancer incidence and mortality in patients with type 2 diabetes. Proposed mechanisms include AMPK-mediated inhibition of the mTOR pathway, reduced insulin-like growth factor signaling, and improved metabolic control. However, randomized controlled trials have not confirmed a definitive protective effect, and metformin is not currently indicated for cancer prevention. Research into metformin’s potential anticancer properties continues to be an active area of investigation, with several large-scale trials ongoing.
Indian Generic Pricing
India is a global hub for affordable generic metformin production. Generic metformin 500 mg tablets are among the most affordable diabetes medications available. A month’s supply (60 tablets of 500 mg) from Indian generic manufacturers typically costs between $1.80–$3.60, compared to brand-name Glucophage in the United States which may range from $9–$27 per month without insurance. Extended-release formulations are slightly more expensive but remain highly cost-effective. Prices vary based on manufacturer, pharmacy, and procurement channel. For a curated selection of quality-assured diabetes medications, visit our Diabetes Medications collection.
Frequently Asked Questions
Does metformin cause weight gain?
Can I take metformin if I have kidney disease?
What is metformin-associated lactic acidosis?
Should I take metformin with food?
Safety Precautions
- Discontinue temporarily before surgery, iodinated contrast procedures, or during acute illness with dehydration.
- Monitor vitamin B12 levels annually in long-term users; supplementation may be required if deficiency develops.
- Avoid excessive alcohol consumption during metformin therapy due to increased risk of lactic acidosis.
- Not recommended for use in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis.
References
- FDA Prescribing Information: Glucophage (metformin hydrochloride). U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/
- American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S158–S178.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998;352(9131):854–865.
- Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.
- World Health Organization. WHO Model List of Essential Medicines – 22nd List, 2021. Geneva: WHO; 2021.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medication. Drug prices shown are approximate ranges and may vary by location, pharmacy, and insurance coverage. Generic medications are bioequivalent to brand-name counterparts but may differ in appearance and excipients.
